---
title: Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal
  large B-cell lymphoma in an adolescent patient
date: '2024-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38406546/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240227170501&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: The safety and efficacy of CAR T-cell therapy are unknown in pediatric
  and adolescent patients with relapsed or refractory primary mediastinal large B-cell
  lymphoma (R/R PMBCL) which is associated with dismal prognosis. Here, we present
  a case report of a 16-year-old patient with R/R PMBCL treated with lisocabtagene
  maraleucel including correlative studies. Patient achieved complete response at
  6 months without cytokine release syndrome and immune effector cell-associated neurotoxicity
  ...
disable_comments: true
---
The safety and efficacy of CAR T-cell therapy are unknown in pediatric and adolescent patients with relapsed or refractory primary mediastinal large B-cell lymphoma (R/R PMBCL) which is associated with dismal prognosis. Here, we present a case report of a 16-year-old patient with R/R PMBCL treated with lisocabtagene maraleucel including correlative studies. Patient achieved complete response at 6 months without cytokine release syndrome and immune effector cell-associated neurotoxicity ...